Abstract Stockpiling neuraminidase inhibitors (NAIs) such as oseltamivir and zanamivir is part of 6 a global effort to be prepared for an influenza pandemic. However, the contribution of NAIs for 7 treatment and prevention of influenza and its complications is largely debatable. Here, we 
Introduction

18
Influenza A virus (IAV) infection affects about 20% of the worldwide population every year (Moscona, reduce the risk of illness in close contacts of infected persons (Nguyen-Van-Tam et al., 2014). 48 From the available evidence, it can be seen that NAIs require a strict and narrow time window for 49 small treatment effects to be achieved and, in order to have prophylactic effects, healthy individuals 50 need to take the medicine daily for a long period. This is undoubtedly debatable. The review of 51 Jefferson et al. (2014) has suggested that no clinical trials provide concrete evidence for patients, 52 clinicians or policy-makers to use NAIs in annual and pandemic influenza. Furthermore, prophy-53 lactic use was also questionable because virus culture was not performed on all trial participants. 54 Therefore, it is not clear whether this is because participants were not infected or because they had 55 an asymptomatic infection Jefferson and Doshi (2014) . 56 Here, we attempt to clarify these claims both mathematically and computationally. Using a 57 within-host infection model of influenza infection, we evaluate the effectiveness of NAIs in reducing 58 viral load and symptom severity as a function of the initiation time of post-infection treatment. 59 Furthermore, using a contact network model of epidemics, we assess the prophylactic effects of 60 NAIs in a population, and discuss treatment strategies with a focus on the cost and availability of 61 the drugs. Our numerical analysis employs oseltamivir as a case study; however, our results and 62 their implications are applicable to NAIs in general.
63
Results
64
NAIs are unlikely to attain high efficacies even in a best-case scenario 65 Assuming an idealistic case scenario of instantaneous absorption of NAIs by a treated host as described in Materials and Methods-Eq. (12), the quasi-steady states of the drug concentration are given by (details in Appendix 1) (2)
In other words, the drug concentration stabilises to well-defined values after a few doses: an upper bound and a lower bound , respectively (Appendix 1). For a given drug and a given treatment regimen, the value of represents a best-case scenario for the therapy. That is, the simplified system defined by Eqs. (7)-(11), supplemented with This relationship is illustrated in Fig. 1 (6) Figure 2 shows the landscape of peak efficacies for a given drug, assuming that the therapy follows 77 either the curative or the pandemic regimen of oseltamivir.
Here, for the pandemic regimen, we find that in order to achieve a peak efficacy of at least * = 0. The top panels of Figure 3 show the fraction of reduction in the viral load and symptoms AUC in the best-case scenario ( ( ) = * ), which we denote by , with
where AUC T corresponds to the case with treatment and AUC 0 to the base case without treatment.
86
Results are shown for different starting times of the therapy, 0 , in the curative regimen of oseltamivir.
87
The bottom panels of In order to avoid artificial growth of the virus late after infection, simulations with a viral load below a prescribed tolerance-in this case, 10 −3 TCID 50 mL −1 -one day post infection are assumed stop growing, i.e., the right hand side of Eq. (10) becomes − from day 1 onwards for these cases. In all cases, the treatment corresponds to the curative regimen for oseltamivir: 0 = 75 mg, = 0.5 days. 
Materials and Methods
186
Within-host infection dynamics
The within-host model of the dynamics of influenza infection corresponds to the target cell-limited model with delayed virus production originally introduced by Baccam et al. (2006), and later extended by Lukens et al. (2014) in order to consider the effects of the virus on individuals' symptoms.
Here, we extend the model further to take into account the effects of treatment with NAIs. The full system of equations is given bẏ
The system considers a population of target (epithelial) cells, divided into susceptible ( ), infected Table 1 . The Python code for this 215 section can be visited at systemsmedicine/neuraminidase-inhibitors. Table 1 . Parameter values of the within-host model, Eqs. (7)- (12) In this way, changes in epidemic trajectories can be attributed solely to the drug's effect. 
252
The R code for this section can be visited at systemsmedicine/neuraminidase-inhibitors. We can find the quasi-steady states illustrated in Appendix 1- Fig. 1 by noting that, when we start the therapy, After a time , the initial value of will have decayed by an amount equal to − , so that the drug concentration just before and just after the second administration will be given by where we have used that the interval between intakes is constant and equal to . Repeating this reasoning a few more times we find that, when we reach time , the drug concentration has the form A similar approach can be used to obtain the values to which the peaks and valleys of the drug concentration converge after a long time has passed for the more complicated model
